Search This Blog

Wednesday, September 30, 2020

AtriCure down on Kerrisdale short call

Thinly traded AtriCure (ATRC -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:

The company's Convergent procedure is unlikely to gain traction considering its poor safety profile and lack of incremental benefit compared to catheter-based procedures.

The total available market for its surgical ablation products is much smaller that it claims and is almost completely saturated.

Other approaches, real-time mapping and pulse-field ablation, are set to revolutionize catheter ablation to the detriment of Convergent and the company's core surgical devices business.

https://seekingalpha.com/news/3618422-atricure-down-9-on-kerrisdale-short-call

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.